Edoxaban accepted by NICE for stroke prevention in atrial fibrillation

The direct thrombin inhibitor edoxaban (Lixiana) has been recommended by NICE, within its marketing authorisation, as an option for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

Further information
NICE technology appraisal TA355

Patients are eligible to receive the treatment on the NHS if they have one or more risk factors, including:

  • congestive heart failure
  • hypertension
  • diabetes
  • prior stroke or transient ischaemic attack
  • age 75 years or older.

In August, NICE approved edoxaban for use in treating and preventing recurrent deep vein thrombosis and pulmonary embolism in adults.

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.